Yuta Ito
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yuta Ito has a total of 187 co-authors. Here are the top co-authors by number of shared publications:
- Keisuke Kataoka
Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan; Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
55 shared publications - Yasunori Kogure
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
55 shared publications - Junji Koya
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
53 shared publications - Yuki Saito
Division of Molecular Oncology National Cancer Center Research Institute Tokyo Japan
53 shared publications - Mariko Tabata
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
52 shared publications - Koichi Murakami
Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan
51 shared publications
Latest Publications
- Open Access
- 17 September 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (4)
Steroid exposure is associated with cytomegalovirus reactivation after CAR T-cell therapy for large B-cell lymphomas
- 17 September 2026
- Published by Elsevier in Blood Immunology & Cellular Therapy
- Vol. 2 (4)
Open AccessSteroid exposure is associated with cytomegalovirus reactivation after CAR T-cell therapy for large B-cell lymphomas
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Tables from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Data from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Figures S1-S10, Supplementary Table Legends
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Data from Comprehensive Genetic Profiling Reveals Frequent Alterations of Driver Genes on the X Chromosome in Extranodal NK/T-cell Lymphoma
Supplementary Figures S1-S10, Supplementary Table Legends
- Open Access
- 20 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (15) , 5276-5284
Atezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: the phase II NCCH1903/ATTACK trial
Extranodal NK/T-cell lymphoma (ENKTL) is rare and has limited treatment options available for relapsed/refractory (R/R) disease. This multicenter single-arm phase II study evaluated the efficacy and safety of atezolizumab monotherapy in patients with R/R ENKTL. The primary endpoint was the objective response rate (ORR), as assessed by an independent review committee (IRC). Fourteen patients were ultimately enrolled. Among the 13 with evaluable responses, the median age was 72 (range, 27-80) years, 46% were female, and 77% had Eastern Cooperative Oncology Group Performance Status of 1. The IRC-assessed ORR was 54% (7/13), which included four complete responses (31%). Over a median follow-up period of 24.9 months, the median response duration was not reached. The median progression-free and overall survival were 2.4 and 10.3 months, respectively. Structural variations (SVs) in the programmed cell death-ligand 1 (PD-L1) were detected in 4/11 evaluable patients (36%) via targeted-capture sequencing and/or fluorescence in situ hybridization. The ORR in those patients was 75% (3/4), while 3/7 patients without PD-L1 SVs achieved responses (ORR, 43%). PD-L1 expression was positive in 5/11 evaluable patients (45%) via immunohistochemistry. The ORR in that group was 80% (4/5), vs 33% (2/6) in those without PD-L1 expression. Atezolizumab demonstrated clinically meaningful efficacy with durable responses in patients with R/R ENKTL. PD-L1 genetic alterations and/or PD-L1 expression levels may represent predictive biomarkers of patient responses to this approach. This trial was registered in the Japan Registry for Clinical Trials (jRCT2031190177).
- 20 May 2026
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (15) , 5276-5284
Open AccessAtezolizumab for relapsed/refractory extranodal NK/T-cell lymphoma: the phase II NCCH1903/ATTACK trial
Extranodal NK/T-cell lymphoma (ENKTL) is rare and has limited treatment options available for relapsed/refractory (R/R) disease. This multicenter single-arm phase II study evaluated the efficacy and safety of atezolizumab monotherapy in patients with R/R ENKTL. The primary endpoint was the objective response rate (ORR), as assessed by an independent review committee (IRC). Fourteen patients were ultimately enrolled. Among the 13 with evaluable responses, the median age was 72 (range, 27-80) years, 46% were female, and 77% had Eastern Cooperative Oncology Group Performance Status of 1. The IRC-assessed ORR was 54% (7/13), which included four complete responses (31%). Over a median follow-up period of 24.9 months, the median response duration was not reached. The median progression-free and overall survival were 2.4 and 10.3 months, respectively. Structural variations (SVs) in the programmed cell death-ligand 1 (PD-L1) were detected in 4/11 evaluable patients (36%) via targeted-capture sequencing and/or fluorescence in situ hybridization. The ORR in those patients was 75% (3/4), while 3/7 patients without PD-L1 SVs achieved responses (ORR, 43%). PD-L1 expression was positive in 5/11 evaluable patients (45%) via immunohistochemistry. The ORR in that group was 80% (4/5), vs 33% (2/6) in those without PD-L1 expression. Atezolizumab demonstrated clinically meaningful efficacy with durable responses in patients with R/R ENKTL. PD-L1 genetic alterations and/or PD-L1 expression levels may represent predictive biomarkers of patient responses to this approach. This trial was registered in the Japan Registry for Clinical Trials (jRCT2031190177).
- Open Access
- 23 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases
Targeted genes in each gene panel
- 23 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases
Targeted genes in each gene panel
- Open Access
- 23 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S9 from Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases
GSEA analyses comparing samples with and without driver mutations in epigenetic regulators in 6 cancer types/subtypes
- 23 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S9 from Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases
GSEA analyses comparing samples with and without driver mutations in epigenetic regulators in 6 cancer types/subtypes
- Open Access
- 23 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S8 from Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases
Analysis of co-occurring and mutually exclusive relationships
- 23 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S8 from Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases
Analysis of co-occurring and mutually exclusive relationships
- Open Access
- 23 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S7 from Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases
Frequency of mutated samples for 352 recurrent driver gene–cancer type combinations
- 23 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S7 from Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases
Frequency of mutated samples for 352 recurrent driver gene–cancer type combinations
- Open Access
- 23 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S1 from Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases
Number of samples in 26 principal cancer types/subtypes
- 23 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S1 from Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases
Number of samples in 26 principal cancer types/subtypes
- Open Access
- 23 March 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases
Details of driver CNAs in C-CAT
- 23 March 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Pan-Cancer Comparative and Integrative Analyses of Driver Alterations Using Japanese and International Genomic Databases
Details of driver CNAs in C-CAT